Abstract Details

Title Histamine 2 Blockers And Nimodipine In Aneurysmal Subarachnoid Hemorrhage Patients

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 097

Objective To determine the effect of H2 blockers on outcome of SAH patients being treated with nimodipine on outcomes.

Background Histamine (H) 2 blockers led to a significant increase of the relative bioavailability of nimodipine and therefore may change tolerability of nimodipine in patients with aneurysmal subarachnoid hemorrhage (SAH).

Design/Methods We analyzed data from Cerner Health Facts® which collected data from participating facilities from January 1st, 2000 to July 1st, 2018. We identified SAH patients who underwent endovascular or surgical treatment for intracranial aneurysm and received nimodipine with or without H2 blockers. Outcome was defined by discharge destination and classified into none to minimal disability, moderate to severe disability, or death.

Results A total of 815 (54.8%) of 1488 SAH patients received H2 blockers in addition to nimodipine. There were no differences in rates of cerebral ischemia (8.8% versus 9.8%) or performance of angioplasty (3.8% versus 3.7%) between patients who did or did not receive H2 blockers. There were no differences in rates of intubation/mechanical ventilation (26.0% versus 29.3%) or intra-procedural cerebral infarction (3.4% versus 2.8%) between the two groups. There was no difference in in hospital mortality rates (10.9% versus 10.2%) or none to minimal disability (41.8% versus 38.2%) between patients who did or did not receive H2 blockers.

Conclusions H2 blockers are frequently used with nimodipine in SAH patients and did not appear to adversely affect rates of death or disability. The finding does not support any clinically significant interaction between H2 blockers and nimodipine in SAH patients.

Authors/Disclosures
Hamza I. Maqsood, MD (Dept of Neurology) PRESENTER	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.
	No disclosure on file
	No disclosure on file
Muhammad F. Ishfaq, MD	Dr. Ishfaq has nothing to disclose.
Nitish Kumar, MD	Dr. Kumar has nothing to disclose.
	No disclosure on file
	No disclosure on file
Niraj A. Arora, MD (University of Missouri, Columbia)	Dr. Arora has nothing to disclose.
Premkumar Nattanmai Chandrasekaran, MD (UMHS)	Dr. Nattanmai Chandrasekaran has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB pharma.
Farhan Siddiq, MD	Dr. Siddiq has nothing to disclose.
Camilo R. Gomez, MD, F�鶹��ýӳ�� (University of Missouri)	Dr. Gomez has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��